Also known as: SystImmune
SystImmune is a U.S.-based biopharmaceutical company developing multi-specific antibodies and ADCs for cancer treatment. It was founded in 2014 in Redmond, Washington and is a member of the Biokin Pharmaceutical group.
Bristol Myers Squibb and SystImmune reported that antibody-drug conjugate izalontamab brengitecan achieved statistically significant improvements in both progression-free and overall survival versus chemotherapy in a Phase III trial for triple-negative breast cancer.
Izalontamab brengitecan demonstrated statistically significant improvements in progression-free survival and overall survival compared to chemotherapy in patients with previously treated metastatic triple-negative breast cancer, marking the third Phase III success for the bispecific ADC.
